Hyderabad Pharma Firm Signs Agreement To Make Covid Drug 2-DG

An integrated pharmaceutical company, Lee Pharma entered into the non-exclusive licensing agreement for the synthesis of 2-DG, recently developed by DRDO and Dr Reddy's Laboratories.

Hyderabad-based Lee Pharma has entered into an agreement with the Indian Institute of Chemical Technology (IICT), a constituent laboratory of CSIR, to manufacture and commercialise 2-Deoxy-D-Glucose (2-DG) used to treat Covid patients, a statement said on Wednesday. An integrated pharmaceutical company, Lee Pharma entered into the non-exclusive licensing agreement for the synthesis of 2-DG, recently developed by DRDO and Dr Reddy's Laboratories. The drug has received approval for use in COVID-19 patients. It has been found to help speed up recovery and reduce oxygen dependence, and Dr. Reddy''s Laboratories has launched the drug in the form of sachets. Lee Pharma informed that they would file the application for getting the approval from the drug regulator.